Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.

ABSTRACT:

Objectives

In two Phase III studies, lisdexamfetamine dimesylate (LDX) reduced binge eating (BE) days/week in adults with moderate to severe binge eating disorder (BED) and was associated with improvement based on the Clinical Global Impressions-Improvement (CGI-I) scale. In this study, post hoc analyses examined the relationships between clinical observations and clinical rating scales in individuals with BED.

Clinical trial registration

NCT01718483 (ClinicalTrials.gov/ct2/show/NCT01718483); NCT01718509 (ClinicalTrials.gov/ct2/show/NCT01718509).

Methods

Two 12-week, double-blind, placebo-controlled studies randomized (1:1) adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, BED criteria and with protocol-defined

SUBMITTER: Citrome L 

PROVIDER: S-EPMC5819587 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature